Phase I pharmacodynamic study evaluating gastric pH control with PA 10040, POZEN's aspirin (100mg)/omeprazole (40mg)

Trial Profile

Phase I pharmacodynamic study evaluating gastric pH control with PA 10040, POZEN's aspirin (100mg)/omeprazole (40mg)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs Aspirin/omeprazole (Primary)
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced ulcer
  • Focus Pharmacodynamics; Registrational
  • Sponsors POZEN
  • Most Recent Events

    • 08 May 2014 According to a Pozen media release, this trial will be completed by 2014.
    • 08 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top